NCT06780098 - Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

March 2, 2032

Study Completion Date

March 2, 2032

Conditions

Lung Neoplasm

Interventions

BIOLOGICAL

R-DXD

IV Infusion

BIOLOGICAL

I-DXD

IV Infusion

DRUG

Docetaxel

IV Infusion

Trial Locations (14)

6000

RECRUITING

Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063), Kecskemét

21237

RECRUITING

MedStar Franklin Square Medical Center ( Site 0033), Baltimore

28223

RECRUITING

Hospital Universitario Quiron Madrid ( Site 0091), Madrid

3109601

RECRUITING

Rambam Health Care Campus ( Site 0076), Haifa

4428164

RECRUITING

Meir Medical Center ( Site 0071), Kfar Saba

4941492

RECRUITING

Rabin Medical Center ( Site 0074), Petah Tikva

5265601

RECRUITING

Sheba Medical Center ( Site 0070), Ramat Gan

6423906

RECRUITING

Sourasky Medical Center ( Site 0077), Tel Aviv

7500653

RECRUITING

Centro de Estudios Clínicos SAGA ( Site 0161), Santiago

7500921

RECRUITING

FALP ( Site 0160), Santiago

9103102

RECRUITING

Shaare Zedek Medical Center ( Site 0075), Jerusalem

40536-0293

RECRUITING

University of Kentucky Chandler Medical Center ( Site 0019), Lexington

60-569

RECRUITING

Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153), Poznan

80-214

RECRUITING

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150), Gdansk